Heron Therapeutics Inc (NASDAQ:HRTX) Expected to Post Quarterly Sales of $31.91 Million

Equities analysts predict that Heron Therapeutics Inc (NASDAQ:HRTX) will announce sales of $31.91 million for the current quarter, Zacks reports. Four analysts have provided estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $34.60 million and the lowest estimate coming in at $26.80 million. Heron Therapeutics posted sales of $17.28 million in the same quarter last year, which would indicate a positive year over year growth rate of 84.7%. The firm is scheduled to report its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year sales of $119.99 million for the current year, with estimates ranging from $114.40 million to $124.85 million. For the next year, analysts anticipate that the firm will report sales of $213.63 million, with estimates ranging from $185.00 million to $253.70 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The firm had revenue of $31.60 million during the quarter, compared to analyst estimates of $28.04 million. During the same period in the prior year, the business earned ($1.09) EPS. The business’s revenue for the quarter was up 172.4% compared to the same quarter last year.

Several analysts have issued reports on HRTX shares. BidaskClub raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 18th. ValuEngine raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 22nd. Northland Securities set a $55.00 price target on Heron Therapeutics and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $38.00 price target on shares of Heron Therapeutics in a research note on Wednesday, May 1st. Finally, Cowen reissued a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $48.20.

Shares of HRTX traded up $0.15 during midday trading on Wednesday, hitting $18.97. The stock had a trading volume of 53,586 shares, compared to its average volume of 1,016,996. The firm has a 50 day moving average of $17.97. Heron Therapeutics has a twelve month low of $16.20 and a twelve month high of $41.55. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.77 and a beta of 1.59. The company has a current ratio of 4.40, a quick ratio of 4.06 and a debt-to-equity ratio of 0.04.

In related news, Director Waage Christian bought 1,400 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were acquired at an average price of $18.04 per share, with a total value of $25,256.00. Following the completion of the transaction, the director now owns 1,400 shares in the company, valued at $25,256. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Poyhonen bought 3,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was bought at an average cost of $17.55 per share, for a total transaction of $52,650.00. Following the transaction, the director now owns 13,000 shares of the company’s stock, valued at approximately $228,150. The disclosure for this purchase can be found here. 12.56% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of HRTX. Private Asset Management Inc. increased its holdings in shares of Heron Therapeutics by 3.8% during the second quarter. Private Asset Management Inc. now owns 95,950 shares of the biotechnology company’s stock worth $1,784,000 after buying an additional 3,495 shares in the last quarter. First Trust Advisors LP increased its holdings in Heron Therapeutics by 6.1% in the first quarter. First Trust Advisors LP now owns 75,331 shares of the biotechnology company’s stock valued at $1,841,000 after purchasing an additional 4,335 shares during the period. FMR LLC increased its holdings in Heron Therapeutics by 5.5% in the first quarter. FMR LLC now owns 8,473,847 shares of the biotechnology company’s stock valued at $207,101,000 after purchasing an additional 439,044 shares during the period. Clearbridge Investments LLC increased its holdings in Heron Therapeutics by 153.4% in the first quarter. Clearbridge Investments LLC now owns 2,180,577 shares of the biotechnology company’s stock valued at $53,293,000 after purchasing an additional 1,320,025 shares during the period. Finally, Belpointe Asset Management LLC acquired a new stake in Heron Therapeutics in the first quarter valued at $323,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.